The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression
Abstract
OBJECTIVES: To study and update the clinical characteristics and long-term outcome of our patients with mycosis fungoides (MF) and Sézary syndrome (SS), and to identify important clinical factors predictive of survival and disease progression. DESIGN: A single-center, retrospective cohort analysis. SETTING: Academic referral center for cutaneous lymphoma. PATIENTS: Five hundred twenty-five patients with MF and SS evaluated and managed at Stanford University Cutaneous Lymphoma Clinic, Stanford, Calif, from 1958 through 1999. MAIN OUTCOME MEASURES: We calculated long-term actuarial overall and disease-specific survivals and disease progression by the Kaplan-Meier method, and relative risk (RR) for survival calculated from expected survivals in control populations. RESULTS: The majority of our patients presented with T1 (30%) or T2 (37%) disease; 18% presented with T3 and 15% with T4 skin involvement. Forty-three percent of deaths were attributable to MF, primarily in patients with T3 or T4 disease. The patients with a more advanced T classification and clinical stage had a worse survival outcome. Except for patients with T1 or stage IA disease, the RR for death is greater in patients with MF than in a control population (RR, 2.2 in stage IB/IIA disease, 3.9 in stage IIB/III disease, and 12.8 in stage IV disease). Despite similar overall survival in patients with stage IB or IIA disease, their disease-specific survivals were significantly different (P =.006). The most significant clinical prognostic factors in the univariate analysis were patient age, TNM and B classifications, overall clinical stage groupings, and the presence or absence of extracutaneous disease. In the multivariate analysis, patient age, T classification, and the presence of extracutaneous disease were the most important independent factors. The risk for disease progression to a more advanced TNM or B classification, worse clinical stage, or death due to MF correlated with the severity of the initial T classification. The risk for development of extracutaneous disease also correlated with T classification; none of these patients had T1 disease when their extracutaneous disease was detected. CONCLUSIONS: Patients with MF and SS have varying risks for disease progression or death. The most important clinical predictive factors for survival include patient age, T classification, and the presence of extracutaneous disease. The significant disease-specific survival differences between different clinical stages validate the usefulness of the present MF clinical staging system of the National Cancer Institute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Vonderheid, E. C., Bernengo, M. G., Burg, G., Duvic, M., Heald, P., Laroche, L., Olsen, E., Pittelkow, M., Russell-Jones, R., Takigawa, M., et al. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.118538 · Cited by 493
Mycosis Fungoides: Disease Evolution and Prognosis of 309 Dutch Patients
van Doorn, R., Van Haselen, C. W., van Voorst Vader, P. C., Geerts, M.-L., Heule, F., de Rie, M., Steijlen, P. M., Dekker, S. K., van Vloten, W. A., & Willemze, R. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.4.504 · Cited by 367
Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
Diamandidou, E., Colome-Grimmer, M., Fayad, L., Duvic, M., & Kurzrock, R. (1998) · Blood · doi:10.1182/blood.v92.4.1150 · Cited by 334
Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients
Zackheim, H. S., Amin, S., Kashani-Sabet, M., & McMillan, A. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70491-3 · Cited by 294
Histopathologic Staging at Initial Diagnosis of Mycosis Fungoides and the Sézary Syndrome
Sausville, E. A., Eddy, J. L., Makuch, R. W., Fischmann, A. B., Schechter, G. P., Matthews, M., GLATSTEIN, E. J., Ihde, D. C., Kaye, F., Veach, S. R., et al. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-5-372 · Cited by 268
Vergier, B., Muret, A. D., Beylot-Barry, M., Vaillant, L., Ekouévi, D. K., Chêne, G., Carlotti, A., Franck, N., Dechelotte, P., Souteyrand, P., et al. (2000) · PubMed · doi:10.1182/blood.v95.7.2212 · Cited by 263
Hoppe, R. T., Medeiros, L. J., Warnke, R. A., & Wood, G. S. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)90067-5 · Cited by 182
Self-citationMycosis Fungoides and Sézary Syndrome
Stuver, Moskowitz, Noor, & Horwitz, A. (2023) · Cancer Consult · doi:10.1002/9781119823193.ch49 · Cited by 172
Kim, Y. H., Chow, S., Varghese, A., & Hoppe, R. T. (1999) · Archives of Dermatology · doi:10.1001/archderm.135.1.26 · Cited by 172
Self-citationPrognostic factor analysis in mycosis fungoides/Sézary syndrome
Diamandidou, E., Colome, M., Fayad, L., Duvic, M., & Kurzrock, R. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70079-4 · Cited by 172
Fraser-Andrews, E. A., Woolford, A. J., Russell-Jones, R., Whittaker, S. J., & Seed, P. T. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00830.x · Cited by 161
Bernengo, M. G., Quaglino, P., Novelli, M., Cappello, N., Doveil, G. C., Lisa, F., Matteis, A. D., Fierro, M. T., & Appino, A. (1998) · Annals of Oncology · doi:10.1023/a:1008397323199 · Cited by 116
The changing survival of patients with mycosis fungoides
Weinstock, M. A., & Reynes, J. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1<208::aid-cncr28>3.0.co;2-2 · Cited by 97
Prognostic Clinicopathologic Factors in Cutaneous T-cell Lymphoma
Marti, R. (1991) · Archives of Dermatology · doi:10.1001/archderm.1991.01680090075007 · Cited by 96
Role of histology in providing prognostic information in mycosis fungoides
Smoller, B. R., Detwiler, S. P., Köhler, S., Hoppe, R. T., & Kim, Y. H. (1998) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1998.tb01751.x · Cited by 35
Self-citation
Cited by
WHO-EORTC classification for cutaneous lymphomas
Willemze, R. (2005) · Blood · doi:10.1182/blood-2004-09-3502 · Cited by 3,803
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-055749 · Cited by 1,429
Self-citationOlsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Self-citationThiers, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70989-4 · Cited by 974
Agar, N. S., Wedgeworth, E., Crichton, S., Mitchell, T. J., Cox, M., Ferreira, S., Robson, A., Calonje, E., Stefanato, C. M., Wain, E. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7665 · Cited by 853
Metadata
- Authors
- Kim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., & Hoppe, R. T.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-07-01
- Volume
- 139
- Issue
- 7
- Pages
- 857-66
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2140608535
- Cited by
- 653
- References
- 20
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.